US FDA declines to approve Disc Medicine's rare disease drug

Core Viewpoint - The U.S. Food and Drug Administration (FDA) has declined to approve Disc Medicine's experimental drug bitopertin for treating erythropoietic protoporphyria, leading to a significant drop in the company's stock price by 31.6% to $48.90 [1]. Company Summary - Disc Medicine was seeking FDA approval for bitopertin, aimed at treating a rare genetic metabolic disorder caused by a deficiency of the ferrochelatase enzyme [1]. - The primary symptom of erythropoietic protoporphyria is hypersensitivity of the skin to sunlight [1].